<DOC>
	<DOC>NCT01420081</DOC>
	<brief_summary>This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.</brief_summary>
	<brief_title>A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer</brief_title>
	<detailed_description>The study was prematurely discontinued due to lack confidence in the Stathmin assay as a patient selection criteria and subsequent lack of confidence in the efficacy signal that was observed. The decision to terminate the study was made on January 23, 2014. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Recurrent endometrial carcinoma Disease progression following one or two lines of prior treatment with platinum containing chemotherapy Tumor tissue available at time of screening for PI3K analysis Adequate performance status Adequate glucose control, bone marrow, kidney, liver, and heart function More than 2 prior cytotoxic chemo regimens for endometrial carcinoma Prior therapy with an agent known to be a PI3K, and or mTOR and or AKT inhibitor Active brain metastases</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>uterine neoplasms</keyword>
	<keyword>endometrial</keyword>
	<keyword>uterine</keyword>
	<keyword>cancer</keyword>
	<keyword>PI3K</keyword>
	<keyword>mTOR</keyword>
	<keyword>PI3K/mTOR</keyword>
	<keyword>recurrent</keyword>
	<keyword>metastatic</keyword>
</DOC>